- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03544476
Mobile Health Intervention for Active Tuberculosis
Interactive Mobile Health Intervention to Support Patients With Active Tuberculosis
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tuberculosis (TB) remains a top ten leading cause of death globally despite it being a largely curable disease. New effective treatment supervision strategies are needed particularly in low-resource high TB burden settings and a potential solution is in the hands of nearly every patient - a mobile phone. Modern modular design mobile phone software applications ("apps") hold great promise to address this unmet need.
Current technologies allows for rapid design modification based on end user needs, implementation of native operating system (e.g., Android) versions for users with inconsistent internet access, and the integration of the patients' experiences with electronic health records using industry standards. Apps can perform multiple functions (e.g., automated reminders, symptom tracking, secure messaging, multi-media education). To date, few TB related apps have focused on patients as users, and none support patient engagement in self-management of their care or direct adherence monitoring. The research objectives are to understand end user needs and other stakeholder needs to build, refine, and pilot test an app to support patients self-administering treatment for active TB.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Province Of Buenos Aires
-
Vicente López, Province Of Buenos Aires, Argentina, 1602
- Hospital Dr. Antonio A. Cetrángolo
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Subject is starting TB treatment for the first time
- Subject has no known TB drug resistance
- Subject is HIV negative (self-reported or documented)
- Subject owns or has regular access to a mobile phone that can access the Internet and is able to operate the mobile phone to communicate or have someone able to assist.
Exclusion Criteria:
- Severely ill (i.e., requiring hospitalization)
- Reside in the same household with another study participant
- History of known drug resistance and HIV co-infection because their care is managed separately and the treatment regimens and duration differ.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Mobile phone TB treatment support app
Daily use of the mobile phone TB treatment support app plus usual care.
Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
|
The behavioral intervention is delivered through a mobile phone TB support app.
The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report.
The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app.
The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician.
In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
|
Comparador activo: Usual care
Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician.
In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
|
Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician.
In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Acceptability (perceived usefulness and ease of use)
Periodo de tiempo: 6 months
|
The Mobile Application Rating Scale (MARS) is a 19-item.
The scale includes three sections and a modifiable app-specific section: classification, quality and satisfaction classification section provides descriptive information about the apps.
The objective app quality section includes 19-items divided into four scales: engagement, functionality, aesthetics and information quality.
The subjective quality section contains 4 items evaluating the user's overall satisfaction.
MARS items are scored using a 5-point Likert scale.
The final MARS scores include four subscale scores, a total mean score, subjective quality score and an app-specific subscale that assesses perceived impact on the user's knowledge, attitudes, and intentions to change as well as likelihood of changing targeted behaviors.
|
6 months
|
Feasibility of implementation
Periodo de tiempo: 6 months
|
Semi-structured interview with participants to understand challenges, recommendations for improvement.
Observations
|
6 months
|
Initial efficacy - Treatment outcome
Periodo de tiempo: 6 months
|
Treatment outcomes will be measured using standard definitions set by the World Health Organization (WHO) Standards of TB treatment.
Treatment success based on WHO definitions: completed (without bacteriological confirmation) or cured (negative sputum smear at 6 months and at least once prior to 6 months)).
Other treatment outcomes include: failed (sputum smear positive at 5 months or later), died, defaulted (treatment interruption for ≥ 2 months), lost to follow-up (diagnosed, treatment outcome not documented), or transferred out (transferred to another reporting unit and treatment outcome is unknown).
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Global Health Patient-Reported Outcomes Measurement Information System (PROMIS) short form
Periodo de tiempo: day 1 and 6 months
|
The Global Health short form (SF) is a recommended outcome measure for self-management, includes 10 items
|
day 1 and 6 months
|
Tuberculosis Knowledge Assessment Questionnaire
Periodo de tiempo: day 1 and 6 months
|
Items include questions focused on exploring knowledge about: causes and symptoms of TB (5 items), TB transmission (4 items), TB treatment (2 items), and TB prevention (5 items).
The questions are structured to answer (yes, no, I don't know).
|
day 1 and 6 months
|
Engagement
Periodo de tiempo: 6 months
|
Level of engagement using the app will be measured by percentage of notification without a reminder, number of questions, number of reported side effects.
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Sarah Iribarren, PhD, RN, University of Washington
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY00002080
- K23NR017210 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Tuberculosis
-
Assistance Publique - Hôpitaux de ParisTerminadoTuberculosis extrapulmonar | Tuberculosis de los ganglios linfáticos | Tuberculosis óseaFrancia
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... y otros colaboradoresActivo, no reclutandoTuberculosis | Tuberculosis multirresistente | Tuberculosis resistente a la rifampicina | Tuberculosis extremadamente resistente a los medicamentos | Pre-TB-XDRSudáfrica
-
Huashan HospitalShanghai First Maternity and Infant HospitalDesconocidoInfertilidad Femenina | Fallo de implantación recurrente | Tuberculosis Genital Femenina | Tuberculosis Genital, LatentePorcelana
-
Global Alliance for TB Drug DevelopmentTerminadoTuberculosis | Tuberculosis Pulmonar | Enfermedad pulmonar | Tuberculosis multirresistente | Tuberculosis sensible a fármacos | Tuberculosis resistente a los medicamentos | Infección por Mycobacterium TuberculosisEstados Unidos
-
Global Alliance for TB Drug DevelopmentTerminadoTuberculosis | Tuberculosis Pulmonar | Enfermedad pulmonar | Tuberculosis multirresistente | Tuberculosis sensible a fármacos | Tuberculosis resistente a los medicamentos | Infección por Mycobacterium TuberculosisEstados Unidos
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University of Liverpool; Ministry... y otros colaboradoresTerminadoTuberculosis multirresistente | Tuberculosis Pulmonar | Tuberculosis extremadamente resistente a los medicamentosBielorrusia, Sudáfrica, Uzbekistán
-
University Medical Center GroningenTerminadoTuberculosis multirresistente | Tuberculosis extremadamente resistente a los medicamentosPaíses Bajos
-
Johns Hopkins UniversityUnited States Agency for International Development (USAID)Aún no reclutandoTuberculosis | Tuberculosis Pulmonar | Tuberculosis micobacteriana | Tuberculosis, Nódulo LinfáticoUganda, Sudáfrica, Mozambique, Indonesia, Zambia
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University College, London; University... y otros colaboradoresActivo, no reclutandoTuberculosis multirresistente | Tuberculosis pulmonar | Tuberculosis extremadamente resistente a los medicamentosBielorrusia, Sudáfrica
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free State...ReclutamientoTuberculosis resistente a los medicamentos | Tuberculosis resistente a la rifampicina | Tuberculosis Pulmonar | Tuberculosis resistente a múltiples fármacosSudáfrica